Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Enrolling by invitation Not applicable Interventional

Pilot Trial of Mobile Technology for Adolescent Suicidality

NCT06454136
View directory record Official record
Conditions
Suicidal Ideation
Interventions
OTX-207, Comparator App + Treatment as Usual (TAU)
Device
Lead sponsor
Oui Therapeutics, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Hartford, Connecticut • Cincinnati, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

NCT03931993
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo comparator, Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Edison, New Jersey • Ocean City, New Jersey • Springfield, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 24, 2026, 6:54 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

NCT07499544
View directory record Official record
Conditions
Chronic Hepatitis D Infection
Interventions
Libevitug 20 mg/kg, Libevitug 10 mg/kg, Delayed treatment with libevitug
Drug · Other
Lead sponsor
Huahui Health
Industry
Eligibility
12 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

NCT01652716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide once weekly suspension, Exenatide twice daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
58
States / cities
Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 24, 2026, 6:54 AM EDT
Terminated No phase listed Observational

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

NCT04353921
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
No intervention will be administered as part of this study.
Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lauderhill, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 24, 2026, 6:54 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

NCT02228304
View directory record Official record
Conditions
Macular Degeneration
Interventions
NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
Drug
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

NCT00368108
View directory record Official record
Conditions
Parkinson's Disease
Interventions
2 mg perampanel, 4 mg perampanel, placebo comparator
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
99
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Helping Eliminate Marijuana Use Through Pediatric Practice

NCT02744118
View directory record Official record
Conditions
Marijuana
Interventions
5A's Model, Healthy Internet Use Model
Other
Lead sponsor
American Academy of Pediatrics
Other
Eligibility
13 Years to 25 Years
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 24, 2026, 6:54 AM EDT
Active, not recruiting Not applicable Interventional

Wellness App for Sleep Disturbance in Hematological Cancer Patients

NCT05294991
View directory record Official record
Conditions
Cancer, Sleep Disturbance, Anxiety, Depression, Inflammation, Fatigue
Interventions
Wellness app intervention #1, Wellness app intervention #2
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 24, 2026, 6:54 AM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

NCT04083833
View directory record Official record
Conditions
TQT Study
Interventions
Tetrodotoxin, Placebos
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Just-in-time Elastomeric Training and Fit Testing (JET FIT)

NCT03888898
View directory record Official record
Conditions
Infection
Interventions
Reusable respirator fit test and competency evaluation, Control fit test evaluation
Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Trial of Oral Valproic Acid for Retinitis Pigmentosa

NCT01233609
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 24, 2026, 6:54 AM EDT
Recruiting Not applicable Interventional

Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs

NCT06179498
View directory record Official record
Conditions
Hepatitis C
Interventions
Partner Navigation Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Results available

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

NCT02432716
View directory record Official record
Conditions
Down Syndrome
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 24, 2026, 6:54 AM EDT
Not yet recruiting Not applicable Interventional

A Prospective Study Comparing CSF Shunt Flow Between "Virtual Off" and "Flow Permissive" Shunt Valve Settings Using a Wireless, Noninvasive Shunt Flow Sensor

NCT07815314
View directory record Official record
Conditions
Hydrocephalus
Interventions
Rhaeos Shunt Monitoring System (RSMS), ShuntCheck III
Device
Lead sponsor
Rhaeos, Inc.
Industry
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of LY3985297 in Healthy Participants

NCT06395012
View directory record Official record
Conditions
Healthy
Interventions
LY3985297, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 24, 2026, 6:54 AM EDT
Suspended Phase 3 Interventional

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

NCT05924594
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
Interventions
CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 24, 2026, 6:54 AM EDT
Recruiting Not applicable Interventional

NT-II™ Collagen for Joint Discomfort and Function

NCT07119645
View directory record Official record
Conditions
Activity-Related Knee Discomfort, Joint Discomfort, Functional Joint Pain, Functional Knee Pain, Knee Acute and Chronic Pain
Interventions
NT-II™ (240 mg), NT-II™ 480 mg, Glucosamine/Chondroitin
Dietary Supplement
Lead sponsor
Hofseth Biocare ASA
Industry
Eligibility
20 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

NCT02398188
View directory record Official record
Conditions
Central Abdominal Bulging
Interventions
LIPO-202, Placebo
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

NCT01769417
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Placebo, MEDI4893
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of a DeskCycle to Reduce Sedentary Behavior During the Workday

NCT05412797
View directory record Official record
Conditions
Chronic Disease, Reduction, Weight
Interventions
Cycling/Using a DeskCycle, Regular activities
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kent, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 24, 2026, 6:54 AM EDT
Recruiting Phase 3 Interventional

Nebulized Ketamine for the Treatment of Major Depressive Disorder

NCT06752759
View directory record Official record
Conditions
Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System Agents, Neurotransmitter Agents, Physiologic Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptom, Hypnotics and Sedatives, Anti-anxiety Agents, Tranquilizing Agents, Psychotropic Drugs, Anesthetics Agent
Interventions
nebulized ketamine, nebulized midazolam
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 24, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas

NCT01833988
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bi-hormonal Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 20 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 24, 2026, 6:54 AM EDT